| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
28,663 | 29,586 | 39,201 | 42,944 | 58,763 |
|
Cost of Revenue
|
-12,401 | -13,206 | -16,205 | -15,573 | -18,140 |
|
Gross Profit
|
16,262 | 16,380 | 22,996 | 27,371 | 40,623 |
| Selling, General and Administrative Expenses
|
-13,788 | -12,871 | -16,306 | -20,618 | -20,950 |
|
Research and Development Expenses
|
-6,691 | -6,034 | -6,721 | -8,597 | -8,675 |
|
Operating Income/Expenses
|
-20,479 | -18,905 | -23,027 | -29,215 | -29,625 |
|
Total Operating Profit/Loss
|
-4,217 | -2,525 | -31 | -1,844 | 10,998 |
| Total Net Finance Income/Expense
|
-156 | 388 | 415 | 454 | 113 |
| Net Investment Income
|
-743 | -407 | 1,039 | -22 | -406 |
| Irregular Income/Expenses
|
0 | 604 | 0 | -- | 0 |
|
Other Income/Expense, Non-Operating
|
-302 | -302 | 26 | 144 | 630 |
|
Non-Operating Income/Expenses, Total
|
-899 | 283 | 1,480 | 576 | 337 |
|
Pretax Income
|
-5,116 | -2,242 | 1,449 | -1,268 | 11,335 |
|
Provision for Income Tax
|
-2,087 | -1,635 | -375 | -1,534 | -2,537 |
|
Net Income from Continuing Operations
|
-7,203 | -3,877 | 1,074 | -2,802 | 8,798 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-7,203 | -3,877 | 1,074 | -2,802 | 8,798 |
|
Net Income after Non-Controlling/Minority Interests
|
-7,203 | -3,877 | 1,074 | -2,802 | 8,798 |
|
Net Income Available to Common Stockholders
|
-7,203 | -3,877 | 1,074 | -2,802 | 8,798 |
|
Diluted Net Income Available to Common Stockholders
|
-7,203 | -3,877 | 1,074 | -2,802 | 8,798 |
|
Common Dividend per Share
|
0.01 | -- | 0.01 | 0.01 | 0.03 |
| Basic EPS
|
-0.02 | -0.01 | 0.00 | -0.01 | 0.03 |
| Diluted EPS
|
-0.02 | -0.01 | 0.00 | -0.01 | 0.03 |
|
Basic Weighted Average Shares Outstanding
|
340,804.5010 | 341,415.0270 | 343,318.7970 | 348,841.8490 | 350,518.3780 |
|
Diluted Weighted Average Shares Outstanding
|
340,804.5010 | 341,415.0270 | 343,319.5140 | 348,841.8490 | 350,799.5540 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-4,960 | -2,730 | 932 | -1,825 | 11,098 |
|
EBITDA
|
-2,011 | 409 | 5,079 | 1,564 | 13,671 |
|
Normalized EBITDA
|
-1,697 | 317 | 4,045 | 1,743 | 13,305 |
|
Normalized Income
|
-6,961.2200 | -3,947.8400 | 307.5982 | -2,664.1700 | 8,513.9181 |
|
Total Unusual Items
|
314 | -92 | -1,034 | 179 | -366 |
12/31/2022 - 4/8/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade